Lexington, Mass., October 22, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of John Lepore, M.D., to the company’s board of directors. Dr. Lepore brings over 20 years of leadership experience in R&D and drug discovery to KSQ’s…

Lexington, Mass., October 8, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of Anna Truppel-Hartmann, M.D., as Chief Medical Officer. Dr. Truppel-Hartmann brings an accomplished track record in clinical development, medical affairs, patient engagement, and talent development. She…

Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumors Lexington, Mass., September 24, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson)…

Lexington, Mass., August 28, 2024 – KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, today announced that management will participate in the following investor conferences in September 2024: Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY) on Wednesday, September…

Lexington, Mass., June 12, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of TIL in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene…